LATEST NEWS   Natural rubber production was 24.1 pct lower month-on-month at 21,705 tonnes in February 2026 from 28,579 tonnes in January 2026, and fell 39.7 pct year-on-year from 36,005 tonnes in February 2025 -- DOSM | Police need to refine work procedures and deployment of personnel at petrol stations along country’s borders - Saifuddin Nasution | MMEA foiled bid to smuggle out 20kg of syabu worth RM1 mln off Batu Layar beach near Kota Tinggi on April 8 - Tanjung Sedili MMEA Zone acting director | 
BUSINESS • 08/04/2026 05:35 PM

Meiji Pharma Asia Begins Operations In Singapore To Strengthen ASEAN Presence

KUALA LUMPUR, April 8 (Bernama) -- Meiji Seika Pharma Co Ltd has announced that its subsidiary, Meiji Pharma Asia Pte Ltd, commenced operations in Singapore on April 1, marking a strategic move to strengthen its presence in the ASEAN region.

In a statement, the company said the Singapore-based subsidiary will support the commercialisation, marketing and distribution of pharmaceuticals, including vaccines, across the region.

Meiji Seika Pharma aims to become “a leading company in Asia in the field of infectious diseases” under its “Meiji Group 2026 Vision”, leveraging nearly half a century of experience in manufacturing and marketing pharmaceuticals in Thailand and Indonesia.

Singapore will serve as a regional hub for the company’s business and commercial strategies, aimed at enhancing its influence and accelerating growth across ASEAN markets.

Established on Dec 10, 2025, Meiji Pharma Asia will focus on pharmaceuticals for infectious diseases, haematologic cancers and lifestyle-related diseases, with the aim of ensuring reliable supply and contributing to public health in the region.

-- BERNAMA

More News

Categories

Tags